Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.656717
Keywords
pH-responsive nanoparticles; prodrug; Schiff base; control release; drug delivery
Categories
Funding
- National Natural Science Foundation of China [51973226]
- Shenzhen Science and Technology Innovation Committee [JCYJ20180228163446770]
- Youth Innovation Promotion Association CAS [2019031]
Ask authors/readers for more resources
The study demonstrated a pH-responsive PEGylated doxorubicin prodrug that could achieve high drug loading and pH-responsive drug release within tumor cells, with good stability. Furthermore, the nanoparticles showed similar cytotoxicity to MCF-7 tumor cells as free DOX drug, and were able to encapsulate small DOX drugs with enhanced therapeutic effects.
Developing efficacious drug delivery systems for targeted cancer chemotherapy remains a major challenge. Here we demonstrated a kind of pH-responsive PEGylated doxorubicin (DOX) prodrug via the effective esterification and Schiff base reactions, which could self-assemble into the biodegradable micelles in aqueous solutions. Owing to low pH values inside the tumor cells, these PEG-Schiff-DOX nanoparticles exhibited high drug loading ability and pH-responsive drug release behavior within the tumor cells or tissues upon changes in physical and chemical environments, but they displayed good stability at physiological conditions for a long period. CCK-8 assay showed that these PEGylated DOX prodrugs had a similar cytotoxicity to the MCF-7 tumor cells as the free DOX drug. Moreover, this kind of nanoparticle could also encapsulate small DOX drugs with high drug loading, sufficient drug release and enhanced therapeutic effects toward MCF-7 cells, which will be benefited for developing more drug carriers with desirable functions for clinical anticancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available